Setria is also produced in a patented fermentation process
doi:10.1093/ckj/sfz170 Sarbolouki S, Javanbakht MH, Derakhshanian H, et al
Other than saroglitazar, elafibranor, a PPAR / agonist, was tested in a 1-year phase II RCT involving 274 subjects with biopsy-proven NASH, 107 of whom were diabetic: using a modified post hoc primary endpoint, elafibranor resolved NASH in a significant percentage of patients, without worsening of fibrosis, and ameliorated the hepatic and metabolic profile [67]
Image: United States - As brand-name GLP-1 medications like Wegovy and Ozempic continue to carry monthly costs exceeding $1,000 without insurance, MedVi today released a comprehensive overview of cheaper, compounded alternatives available to American patients